| 前收盘价格 | 2.39 |
| 收盘价格 | 2.39 |
| 成交量 | 7,721 |
| 平均成交量 (3个月) | 13,993 |
| 市值 | 10,933,569 |
| 价格/销量 (P/S) | 10.52 |
| 股市价格/股市净资产 (P/B) | 0.720 |
| 52周波幅 | |
| 利润日期 | 27 May 2026 |
| 营业毛利率 | -15.21% |
| 营业利益率 (TTM) | -937.65% |
| 稀释每股收益 (EPS TTM) | -6.00 |
| 季度收入增长率 (YOY) | -96.30% |
| 总债务/股东权益 (D/E MRQ) | 65.87% |
| 流动比率 (MRQ) | 2.28 |
| 营业现金流 (OCF TTM) | -32.35 M |
| 杠杆自由现金流 (LFCF TTM) | -19.19 M |
| 资产报酬率 (ROA TTM) | -21.98% |
| 股东权益报酬率 (ROE TTM) | -20.03% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | BioLineRx Ltd. | 混合的 | 看跌 |
AIStockmoo 评分
0.5
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.50 |
|
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.08% |
| 机构持股比例 | 0.22% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Nemes Rush Group Llc | 31 Dec 2025 | 250 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合